Efficacy
SOLAR-1:
Pivotal randomized, double-blind, placebo-controlled, multicenter phase 3 trial in HR+/HER2-aBC 1 . A total of 572 patients were enrolled in the trial, including 341 patients with a PIK3CA mutation 1...
SOLAR-1:
Pivotal randomized, double-blind, placebo-controlled, multicenter phase 3 trial in HR+/HER2-aBC 1 . A total of 572 patients were enrolled in the trial, including 341 patients with a PIK3CA mutation 1...
Predictable, manageable and reversible side effects while maintaining quality of life 6
As with any medication, side effects may occur when using the combination therapy Tafinlar® (dabrafenib) and Mekinist® (trametinib). The side...
Over the past 10 years, the treatment landscape of SpA went through a substantial change, with an expansion of new therapies and new modes of action. Guidelines and recommendations have been developed to...
While follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma that is generally associated with long remissions, the disease remains incurable and for patients with relapsed/refractory (r/r) FL the prognosis is dismal. The recent...